StockData
Rein Therapeutics, Inc. logo

Rein Therapeutics, Inc. (RNTX) stock

RNTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/30
$0.36−0.04 (-10.90%)

Close on Nov 17, 2026Market cap $30.75MP/E –Yield 0.00%

Rein Therapeutics ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Rein Therapeutics's ebitda for the twelve months ending Dec 31, 2025 was -$50.63M. For fiscal 2025 it was -$50.63M. The highest annual figure on record is -$12.57M in fiscal 2015.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$50.63M–
FY2024Dec 31, 2024-$65.05M–
FY2023Dec 31, 2023-$16.16M–
FY2022Dec 31, 2022-$27.48M–
FY2021Dec 31, 2021-$26.48M–
FY2020Dec 31, 2020-$20.33M–
FY2019Dec 31, 2019-$29.80M–
FY2018Dec 31, 2018-$31.68M–
FY2017Dec 31, 2017-$22.88M–
FY2016Dec 31, 2016-$17.94M–
FY2015Dec 31, 2015-$12.57M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2025Dec 31, 2025-$32.66M–
Q3 FY2025Sep 30, 2025-$5.49M–
Q2 FY2025Jun 30, 2025-$6.87M–
Q1 FY2025Mar 31, 2025-$5.61M–
Q4 FY2024Dec 31, 2024-$42.80M–
Q3 FY2024Sep 30, 2024-$6.07M–
Q2 FY2024Jun 30, 2024-$9.04M–
Q1 FY2024Mar 31, 2024-$7.15M–
Q4 FY2023Dec 31, 2023-$7.24M–
Q3 FY2023Sep 30, 2023-$1.97M–
Q2 FY2023Jun 30, 2023-$1.98M–
Q1 FY2023Mar 31, 2023-$4.97M–
Q4 FY2022Dec 31, 2022-$4.66M–
Q3 FY2022Sep 30, 2022-$6.44M–
Q2 FY2022Jun 30, 2022-$8.00M–
Q1 FY2022Mar 31, 2022-$8.38M–
Q4 FY2021Dec 31, 2021-$6.78M–
Q3 FY2021Sep 30, 2021-$6.75M–
Q2 FY2021Jun 30, 2021-$5.97M–
Q1 FY2021Mar 31, 2021-$6.99M–
Q4 FY2020Dec 31, 2020-$4.18M–
Q3 FY2020Sep 30, 2020-$5.01M–
Q2 FY2020Jun 30, 2020-$4.33M–
Q1 FY2020Mar 31, 2020-$6.81M–
Q4 FY2019Dec 31, 2019-$7.27M–
Q3 FY2019Sep 30, 2019-$7.89M–
Q2 FY2019Jun 30, 2019-$7.35M–
Q1 FY2019Mar 31, 2019-$7.28M–
Q4 FY2018Dec 31, 2018-$6.93M–
Q3 FY2018Sep 30, 2018-$7.41M–
Q2 FY2018Jun 30, 2018-$9.62M–
Q1 FY2018Mar 31, 2018-$7.72M–
Q4 FY2017Dec 31, 2017-$7.00M–
Q3 FY2017Sep 30, 2017-$6.39M–
Q2 FY2017Jun 30, 2017-$4.93M–
Q1 FY2017Mar 31, 2017-$4.57M–
Q4 FY2016Dec 31, 2016-$4.41M–
Q3 FY2016Sep 30, 2016-$4.17M–

More Rein Therapeutics figures

See a number that looks wrong?